Joel D. Cavaness - Mar 10, 2023 Form 4 Insider Report for Arthur J. Gallagher & Co. (AJG)

Signature
/s/ Seth Diehl, by power of attorney
Stock symbol
AJG
Transactions as of
Mar 10, 2023
Transactions value $
-$156,987
Form type
4
Date filed
3/14/2023, 09:30 PM
Previous filing
Mar 10, 2023
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AJG Common Stock (restricted) Award $0 +9.58K $0.00 9.58K Mar 12, 2023 Direct F1
transaction AJG Common Stock (restricted) Options Exercise $0 -9.58K -100% $0.00* 0 Mar 12, 2023 Direct
transaction AJG Common Stock Options Exercise $0 +9.58K +6.87% $0.00 149K Mar 12, 2023 Direct
transaction AJG Common Stock Tax liability -$757K -4.14K -2.78% $182.76 145K Mar 12, 2023 Direct
holding AJG Common Stock (restricted) 1.65K Mar 10, 2023 By Spouse
holding AJG Common Stock 2.02K Mar 10, 2023 By Spouse
holding AJG Common Stock 215 Mar 10, 2023 Gallagher 401(k) plan account

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AJG Phantom Stock Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities $600K +3.23K +2.67% $185.95 124K Mar 10, 2023 Common Stock 3.23K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Performance share units (awarded on March 12, 2020) earned and vested as of March 12, 2023.
F2 Each share of phantom stock represents a right to receive one share of Gallagher common stock.
F3 These shares represent awards under the Age 62 Plan, a nonqualified deferred compensation plan of the Company, which have been deemed invested in Company common stock at the election of the reporting person. Participants vest in these awards when they attain age 62, or after a one-year period for participants who have attained age 61.